The French biotechnology company TxCell SA has signed an option agreement to license its lead cell therapy for inflammatory bowel disease (IBD) to Ferring International Center SA, and simultaneously announced plans to list its shares on Euronext Paris.
Inotrem SA, a French start-up with a new approach for treating sepsis, has raised €18 million in a Series A round, the largest early funding round in Europe so far this year. The company was co-founded in February 2013 by Jean-Jaques Garaud, formerly of Roche.
Galapagos NV of Belgium said it has sold two of its early-stage service companies, BioFocus and Argenta, to Charles River Laboratories International Inc of the US for €134 million. It retains a third service company in Croatia.
The Vectura Group Plc, which develops and sells products for airway-related diseases, has raised £52 million with a primary offering on the London Stock Exchange in connection with its acquisition of Activaero GmbH, a German specialist in vapor delivery devices called nebulisers, for about £108 million.
Circassia Ltd, which is testing a novel immunotherapy for four major allergies, has raised £200 million in an initial public offering on the London Stock Exchange.
AstraZeneca Plc has completed the sale of its largest research facility at Alderley Park in Cheshire UK to Manchester Science Parks, a public-private enterprise, for an undisclosed amount.
Privately-funded Glycotope GmbH of Germany has raised €55 million in additional equity from its investors in order to complete proof-of-concept studies of two antibody therapeutics for cancer that have been developed using glycosylation technology.
Lombard Medical Technologies Plc, a medical device company which is delisting its shares in London and offering them in the United States via a Cayman Islands holding company, reported a 13% increase in 2013 revenues to $7 million and a 52.7% increase in its operating loss to $20 million.
Life Science Partners (LSP) of Amsterdam, the Netherlands has announced the closing of a new fund that will invest in companies with marketable products in the areas of medical technology, diagnostics and e-health. The fund has raised €112 million from private investors.
Verona Pharma Plc, which develops medicines for respiratory diseases, has announced a share placement, subscription, and open offer with the intention of raising up to £14 million before expenses. The funds will be used to develop a compound for COPD.